JP5116207B2 - 神経保護、抗うつおよび抗虚血活性を有する新規アダマンタン誘導体、およびその製造法 - Google Patents

神経保護、抗うつおよび抗虚血活性を有する新規アダマンタン誘導体、およびその製造法 Download PDF

Info

Publication number
JP5116207B2
JP5116207B2 JP2004254373A JP2004254373A JP5116207B2 JP 5116207 B2 JP5116207 B2 JP 5116207B2 JP 2004254373 A JP2004254373 A JP 2004254373A JP 2004254373 A JP2004254373 A JP 2004254373A JP 5116207 B2 JP5116207 B2 JP 5116207B2
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004254373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005075832A (ja
Inventor
フランチェスコ・マコヴェク
ロベルト・アルトゥシ
シモーナ・ツァンツォーラ
ルーチョ・クラウディオ・ロヴァティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rottapharm SpA
Original Assignee
Rottapharm SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm SpA filed Critical Rottapharm SpA
Publication of JP2005075832A publication Critical patent/JP2005075832A/ja
Application granted granted Critical
Publication of JP5116207B2 publication Critical patent/JP5116207B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/30—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to nitro or nitroso groups
    • C07C279/32—N-nitroguanidines
    • C07C279/36—Substituted N-nitroguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2004254373A 2003-09-02 2004-09-01 神経保護、抗うつおよび抗虚血活性を有する新規アダマンタン誘導体、およびその製造法 Expired - Fee Related JP5116207B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000668A ITTO20030668A1 (it) 2003-09-02 2003-09-02 Derivati dell'adamantano dotati di attivita' neuroprotettiva, antidepressiva e anti-ischemica e procedimento per la loro preparazione.
ITTO2003A000668 2003-09-02

Publications (2)

Publication Number Publication Date
JP2005075832A JP2005075832A (ja) 2005-03-24
JP5116207B2 true JP5116207B2 (ja) 2013-01-09

Family

ID=34131246

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004254373A Expired - Fee Related JP5116207B2 (ja) 2003-09-02 2004-09-01 神経保護、抗うつおよび抗虚血活性を有する新規アダマンタン誘導体、およびその製造法

Country Status (9)

Country Link
US (1) US7145037B2 (fr)
EP (1) EP1512679B1 (fr)
JP (1) JP5116207B2 (fr)
AT (1) ATE517079T1 (fr)
AU (1) AU2004206990A1 (fr)
CA (1) CA2479613A1 (fr)
ES (1) ES2369888T3 (fr)
IT (1) ITTO20030668A1 (fr)
PT (1) PT1512679E (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109292A2 (fr) * 2006-03-21 2007-09-27 Wisconsin Alumni Research Foundation Réactifs ionisables d'étiquetage isotopique pour la quantification relative par spectrométrie de masse
WO2007117544A2 (fr) * 2006-04-07 2007-10-18 Ssv Therapeutics, Inc. Conjugés carnitine d'adamantanamines et dérivés de néramexane comme promédicaments doubles pour utilisations variées
EP2117315A1 (fr) * 2007-02-21 2009-11-18 SSV Therapeutics, Inc. Adamantanamines et sels de néramexane d'acides thiomolybdiques et thiotungsténiques
DE102007022007A1 (de) * 2007-05-08 2008-11-13 Schebo Biotech Ag Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes
WO2010019712A1 (fr) * 2008-08-12 2010-02-18 The Trustees Of The University Of Pennsylvania Modulation du virus de la grippe
US8557836B2 (en) * 2008-09-16 2013-10-15 The Trustees Of The University Of Pennsylvania Spiro-piperidine inhibitors
US8592216B2 (en) 2009-04-15 2013-11-26 Wisconsin Alumni Research Foundation Labeling peptides with tertiary amines and other basic functional groups for improved mass spectrometric analysis
WO2011022191A1 (fr) * 2009-08-21 2011-02-24 The Trustees Of The University Of Pennsylvania Analogues d’adamantane
US20110065762A1 (en) * 2009-09-11 2011-03-17 Jizhou Wang Methods of use of antiviral compounds
US8440720B2 (en) * 2009-09-11 2013-05-14 Influmedix, Inc. Methods of use of antiviral compounds
JP5562716B2 (ja) * 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
US9884832B2 (en) 2011-12-06 2018-02-06 The Trustees Of The University Of Pennsylvania Inhibitors targeting drug-resistant influenza A
WO2019104020A1 (fr) 2017-11-22 2019-05-31 Panorama Research, Inc. Composés de nitrate d'aminoadamantyle et leur utilisation pour traiter des troubles du système nerveux central

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28836A (en) * 1860-06-26 Improvement in plows
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
US4007181A (en) * 1974-02-11 1977-02-08 The Upjohn Company Adamantyl containing guanidines
ATE94384T1 (de) 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
EP0532642A1 (fr) 1990-05-25 1993-03-24 STATE OF OREGON, acting through OREGON STATE BOARD OF HIGHER EDUCATION, acting for OREGON HEALTH SC. UNIV. AND UNIV. OF OREGON Guanidines substituees ayant un coefficient de liaison eleve avec le recepteur sigma et utilisation de ces substances
AU1362699A (en) 1997-10-21 1999-05-10 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
GB9726388D0 (en) * 1997-12-12 1998-02-11 Cerebrus Ltd Chemical compounds
GB9802225D0 (en) * 1998-02-02 1998-04-01 Cerebrus Ltd Chemical compounds
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
US6645968B2 (en) 1999-08-03 2003-11-11 Abbott Laboratories Potassium channel openers
ITTO20010110A1 (it) * 2001-02-08 2002-08-08 Rotta Research Lab Nuovi derivati benzamidinici dotati di attivita' anti-infiammatoria ed immunosoppressiva.
US6974869B2 (en) 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
ITTO20030668A1 (it) 2005-03-03
EP1512679B1 (fr) 2011-07-20
AU2004206990A1 (en) 2005-03-17
PT1512679E (pt) 2011-08-03
ES2369888T3 (es) 2011-12-07
ATE517079T1 (de) 2011-08-15
EP1512679A1 (fr) 2005-03-09
US20050049312A1 (en) 2005-03-03
JP2005075832A (ja) 2005-03-24
US7145037B2 (en) 2006-12-05
CA2479613A1 (fr) 2005-03-02

Similar Documents

Publication Publication Date Title
DE69930552T2 (de) Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen
JP5116207B2 (ja) 神経保護、抗うつおよび抗虚血活性を有する新規アダマンタン誘導体、およびその製造法
JP3464800B2 (ja) シナプス応答を増強するベンゾイル−ピペリジン類／ピロリジン類
DE60107435T2 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
JPH06506455A (ja) 神経伝達物質放出調節剤としてのグアニジン置換体及びその誘導体ならびに神経伝達物質放出遮断物質を同定するための新規な方法
CH616668A5 (fr)
JPH07509219A (ja) Ｈ↓３受容体アンタゴニストとしての４−［４’−ピペリジニルまたは３’−ピロリジニル］置換イミダゾールおよび治療上のその使用方法
CA2854622A1 (fr) Modulateurs de recepteurs des opioides et leurs procedes d'utilisation
KR20230004785A (ko) 스피로우레아 유도체
JP2023182589A (ja) フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
EP2681209B1 (fr) Composés et méthodes de traitement de la douleur et d'autres troubles
JP2003508512A (ja) 非ペプチド性サイクロフィリン結合化合物とその用途
JP2021520410A (ja) 多汗症を治療するためのブメタニド誘導体
JP2021073171A (ja) （ｒ）−ジミラセタム（１）と（ｓ）−ジミラセタム（２）を非ラセミ比で含む相乗的組成物
WO2007041936A1 (fr) Isomeres optiques de derives de piperazine d'alcool d'alkyle et leurs sels ainsi que leurs applications
EP2484661B1 (fr) Dérivé de 2,3-dihydro-1h-indène-2-ylurée et son application pharmaceutique
CN102317261B (zh) 三重再摄取抑制剂及其应用方法
JP2000319259A (ja) 神経変性疾患を治療するための化合物
US20110230452A1 (en) Compounds and methods for the treatment of pain and other diseases
CN105792821A (zh) 包含1-茚满硫酰胺衍生物的疼痛治疗剂和/或预防剂
JPS62234029A (ja) 中枢神経賦活剤
SE502323C2 (sv) Användning av N-(2-hydroxietyl)nikotinamidnitrat eller ett farmaceutiskt godtagbart salt därav för framställning av ett läkemedel aktivt för behandling av sjukdomar förbundna med cerebral ischemi
EP0818198A1 (fr) Potentialisation d'un médicament par augmentation de la disponibilité de la sérotonine
CN116023336A (zh) 一种具有Nav1.7钠离子通道靶向抑制作用的化合物及其药物组合物和用途
JP2004196823A (ja) １−（４−ヒドロキシフェニル）−２−（４−ヒドロキシ−４−フェニルピペリジン−１−イル）−１−プロパノールのメシレート・３水和物塩の光学活性化合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110512

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120925

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121016

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151026

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees